<DOC>
	<DOCNO>NCT00057993</DOCNO>
	<brief_summary>RATIONALE : The monoclonal antibody trastuzumab locate breast cancer cell HER2 surface either kill deliver tumor-killing substance without harm normal cell . Estrogen stimulate growth breast cancer cell . Hormone therapy use exemestane may fight breast cancer reduce production estrogen . Combining trastuzumab exemestane may effective treatment breast cancer high amount HER2 . PURPOSE : Phase II trial study effectiveness combine trastuzumab exemestane treat postmenopausal woman metastatic locally advanced HER2-positive breast cancer .</brief_summary>
	<brief_title>Trastuzumab Exemestane Treating Postmenopausal Women With Metastatic Locally Advanced Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy exemestane trastuzumab ( Herceptin ) , term response rate time progression , postmenopausal woman metastatic locally advanced hormone-responsive , HER2/neu positive breast cancer . - Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive trastuzumab ( Herceptin ) IV 30-90 minute day 1 oral exemestane daily . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 18-60 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Stage IV locally advance disease Staged bone scan CT scan chest and/or abdomen within past 6 week HER2/neu positive fluorescent situ hybridization ( 2+ immunohistochemistry ) 3+ immunohistochemistry Measurable disease define 1 follow criterion : At least 1 dimension least 1 cm CT scan imaging scan At least 1 diameter least 1 cm plain xray ( exclude bone lesion ) Palpable lesion diameter least 1 cm caliper OR Evaluable disease define 1 follow criterion : Positive bone scan Palpable mass diameter less 1 cm , mass margin clearly define CT scan xray , diameter less 1 cm Bone scan CA 27.29 bone scan evaluable disease Hormone receptor status : Estrogen receptor and/or progesterone receptor positive PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Postmenopausal 1 follow criterion : 60 year age 45 year age amenorrhea 12 month intact uterus Folliclestimulating hormone level within postmenopausal range Undergone bilateral oophorectomy Performance status ECOG 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin less 1.5 time upper limit normal Renal Creatinine le 2 mg/dL Cardiovascular Ejection fraction great 50 % Other Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy No prior trastuzumab ( Herceptin ) Chemotherapy Prior chemotherapy allow Endocrine therapy No prior exemestane No prior hormonal agent ( except tamoxifen ) Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>